SLANG Worldwide Announces Third Quarter 2023 Financial Results
SLANG Worldwide Announces Third Quarter 2023 Financial Results
Achieved positive cash flow for each operating business unit;
每個運營業務部門都實現了正現金流；
Strong sales growth, with revenue of $9.1 million and $28.4 million, for the three month and nine month periods ending September 30, 2023, increasing 11.4% and 7.4% year-over-year, respectively;
在截至2023年9月30日的三個月和九個月期間，銷售增長強勁，收入爲910萬美元和2,840萬美元，分別同比增長11.4％和7.4％；
Continued improvement in adjusted gross margins1 of 52% in Q3 2023, compared with adjusted gross margins of 49% in Q3 of 2022;
調整後的毛利率持續提高1 2023年第三季度爲52％，而2022年第三季度調整後的毛利率爲49％；
Adjusted gross profit1 of $4.8 million in Q3 2023, compared with $4.0 million in Q3 2022, representing an 18.3% increase year-over-year;
調整後的毛利1 2023年第三季度爲480萬美元，而2022年第三季度爲400萬美元，同比增長18.3％；
$10.8 million in cash and restricted cash at September 30, 2023.
截至2023年9月30日，有1,080萬美元的現金和限制性現金。
Toronto, Ontario--(Newsfile Corp. - November 28, 2023) - SLANG Worldwide Inc. (CNSX: SLNG) (OTCQB: SLGWF) ("SLANG" or the "Company"), a leading global cannabis consumer packaged goods (CPG) company with a diversified portfolio of popular brands, today released financial results for the three and nine months ended September 30, 2023. All figures in this press release are stated in Canadian dollars unless otherwise noted.
安大略省多倫多--（新聞文件公司-2023 年 11 月 28 日）- SLANG 環球公司。 (CNSX: SLNG) (OTCQB: SLGWF) (”俚語“或者”公司“) 是一家全球領先的大麻消費品（CPG）公司，擁有多元化的流行品牌組合，今天發佈了截至2023年9月30日的三個月和九個月的財務業績。除非另有說明，否則本新聞稿中的所有數字均以加元表示。
"The third quarter was another solid quarter for SLANG, with both revenue and gross profit increasing sequentially and year-over-year. Impressively, all our operating business units exceeded expectations for the quarter, with each one cash flow positive on a standalone and operational basis," commented John Moynan, Chief Executive Officer of SLANG. "I believe that these results demonstrate the strength of our proven business model, as we are strategically expanding, successfully operating and adapting to the challenging dynamics of each cannabis market and regulatory environment. To me, our results confirm that SLANG is well-positioned for the future."
“第三季度是SLANG又一個穩健的季度，收入和毛利均連續增長，同比增長。令人印象深刻的是，我們所有的運營業務部門都超出了本季度的預期，每個業務部門在獨立和運營的基礎上均爲正數。” SLANG首席執行官約翰·莫伊南評論道。“我相信，這些結果證明了我們久經考驗的商業模式的力量，因爲我們正在進行戰略擴張，成功運營並適應每個大麻市場和監管環境的挑戰性動態。對我來說，我們的結果證實了SLANG在未來處於有利地位。”
Moynan continued, "Across our geographies, we continue to maintain a leadership position as we scale our operations and position SLANG for continued growth. For example, in Vermont, where we saw rapid market saturation in the retail market, we were able to increase revenue by $1.58 million year-over-year by expanding into the wholesale market which is proving to be a new high-margin revenue channel for SLANG. In Colorado, our ability to be nimble and adapt has allowed us to identify and expand our products in select categories, such as within the vape category segment, to lead and expand our market position. Finally, in Maryland and West Virginia, through our strategic partnership with Trulieve, we have integrated this high-growth channel and demonstrated our ability to effectively compete in the country's most competitive markets in a cost-effective manner. Our strength remains our ability to identify opportunities and to focus on partners and categories where we can be successful."
Moynan繼續說：“在我們各個地區，隨着我們擴大業務規模，SLANG將繼續保持領先地位，並定位SLANG以實現持續增長。例如，在佛蒙特州，我們看到零售市場迅速飽和，通過向批發市場擴張，我們的收入同比增加了158萬美元，事實證明，批發市場是SLANG新的高利潤收入渠道。在科羅拉多州，我們靈活適應的能力使我們能夠在特定類別（例如電子煙類別細分市場）中識別和擴展我們的產品，從而引領和擴大我們的市場地位。最後，在馬里蘭州和西弗吉尼亞州，通過與Trulieve的戰略合作伙伴關係，我們整合了這一高增長渠道，並展示了我們以具有成本效益的方式在該國競爭最激烈的市場中有效競爭的能力。我們的優勢仍然是我們能夠發現機會，專注於可以取得成功的合作伙伴和類別。”
Third Quarter 2023 Financial Summary:
2023 年第三季度財務摘要：
- Revenue from continuing operations for the three months ended September 30, 2023, was $9.10 million, compared with $8.17 million in the three months ended September 30, 2022. The year-over-year increase was primarily driven by an increase of $0.95 million in Core Market sales and $0.19 million in Ecommerce sales, partially offset by a decrease of $0.18 million in our Distribution sales and a decrease of $0.03 million in Emerging Market sales. Within the Core Market segment, the Company experienced growth in Vermont, with sales increasing by $1.58 million, which is offset by a reduction of $0.63 million in sales in Colorado.
- Gross profit of $4.9 million (53% gross margin) in Q3 2023, compared with $3.6 million (44% gross margin) in Q3 2022. Adjusted gross profit1 was $4.8 million (52% adjusted gross margin) in Q3 2023, compared with $4.0 million (49% adjusted gross margin) in Q3 2022, representing an 18.3% increase year-over-year.
- EBITDA1 of $(0.38) million in Q3 2023, compared with $(3.43) million in Q3 2022. The improvement in EBITDA is primarily attributable to a $1.67 million increase in gross profit (excluding depreciation costs), and a reduction of $1.38 million in operating expenses (excluding depreciation) such as insurance and share-based payments.
- Adjusted EBITDA1 of $(0.31) million in Q3 2023, compared with $(1.24 million) in Q3 2022. The reduction in Adjusted EBITDA is primarily attributable to an increase of $1.15 in gross profit before fair value adjustments of biological assets (excluding depreciation costs), offset by $0.22 million increase in operating expenses (excluding depreciation expenses, expected credit losses and share based payments).
- $10.82 million in cash and restricted cash on September 30, 2023, compared to $11.92 million on December 31, 2022 and $10.07 million on June 30, 2023. Additionally, for the nine months ended September 30, 2023, cash flows generated from continuing operating activities was $0.29 million, compared to cash flows used in continuing operating activities of ($6.35 million) for the nine months ended September 30, 2022, an improvement of $6.61 million. In the third quarter, the Company received a $1.63 million Employee Retention Tax Credit from the Internal Revenue Service.
- 截至2023年9月30日的三個月，持續經營收入爲910萬美元，而截至2022年9月30日的三個月中，持續經營收入爲817萬美元。同比增長主要是由核心市場銷售額增長95萬美元和電子商務銷售額增長19萬美元推動的，但部分被分銷銷售額下降18萬美元和新興市場銷售額下降3萬美元所抵消。在覈心細分市場中，該公司在佛蒙特州實現增長，銷售額增長了158萬美元，但被科羅拉多州63萬美元的銷售額減少所抵消。
- 2023年第三季度的毛利爲490萬美元（毛利率爲53％），而2022年第三季度爲360萬美元（毛利率爲44％）。調整後的毛利潤1 2023年第三季度爲480萬美元（調整後毛利率爲52％），而2022年第三季度爲400萬美元（調整後毛利率爲49％），同比增長18.3％。
- EBITDA1 2023年第三季度爲38萬美元，而2022年第三季度爲343萬美元。息稅折舊攤銷前利潤的改善主要歸因於毛利（不包括折舊成本）增加了167萬美元，以及保險和股票支付等運營費用（不包括折舊）減少了138萬美元。
- 調整後 EBITDA1 2023年第三季度爲31萬美元，而2022年第三季度爲124萬美元。調整後息稅折舊攤銷前利潤的減少主要歸因於生物資產公允價值調整前的毛利增加了1.15美元（不包括折舊成本），但被運營支出（不包括折舊費用、預期信貸損失和股票支付）的22萬美元增加所抵消。
- 截至2023年9月30日，現金和限制性現金爲1,082萬美元，而2022年12月31日爲1192萬美元，2023年6月30日爲1007萬美元。此外，在截至2023年9月30日的九個月中，持續經營活動產生的現金流爲29萬美元，而截至2022年9月30日的九個月中，用於持續經營活動的現金流爲635萬美元，增加了661萬美元。在第三季度，公司從美國國稅局獲得了163萬美元的員工留存稅收抵免。
Recent Corporate Developments:
公司近期發展：
- The Company announced on November 21, 2023, that it has retained PGP Capital Advisors, LLC, ("PGP") to assist in a review of its strategic alternatives. The Company's Board of Directors has formed a committee of independent directors to assist SLANG's management team and PGP in exploring, reviewing, and evaluating strategic alternatives that may be available to the Company to maximize shareholder value.
- The Company also announces that as of November 14, 2023, it has issued 2,946,757 common shares in connection with the CFO's employment agreement and 5,575,781 common shares in connection with the CEO's employment agreement (the "CEO Agreement"). This was the third and final tranche issuance pursuant to the CEO Agreement, the second tranche was completed May 15, 2023, by the issuance of 1,949,723 common shares and the first tranche completed May 16, 2022, with the issuance of 243,847 common shares.
- 該公司於2023年11月21日宣佈，已聘請PGP Capital Advisors, LLC（“PGP”）來協助審查其戰略替代方案。公司董事會成立了一個由獨立董事組成的委員會，以協助SLANG的管理團隊和PGP探索、審查和評估公司爲實現股東價值最大化而可能採用的戰略替代方案。
- 公司還宣佈，截至2023年11月14日，它已發行了與首席財務官的僱傭協議相關的2,946,757股普通股，併發行了與首席執行官僱傭協議（“首席執行官協議”）相關的5,575,781股普通股。這是根據首席執行官協議進行的第三批也是最後一批發行，第二批於2023年5月15日完成，發行了1,949,723股普通股，第一批於2022年5月16日完成，發行了243,847股普通股。
Third Quarter 2023 Financial Review
2023 年第三季度財務回顧
The consolidated financial statements were prepared in accordance with IFRS. The following is a selected presentation of the Income Statement for the three and nine months ended September 30, 2023.
合併財務報表按照《國際財務報告準則》編制。以下是截至2023年9月30日的三個月和九個月的損益表的精選列報表。
| (In thousands of Canadian dollars except per share data and percentages) | |
For the three months ended | For the nine months ended | | ||||||||
| 30-Sep-23 | 30-Sep-22 | 30-Sep-23 | 30-Sep-22 | |||||||||
| Net Operating Revenue From Continuing Operations | 9,101 | 8,170 | 28,360 | 26,412 | ||||||||
| Cost of goods sold | 4,348 | 4,153 | 13,389 | 14,489 | ||||||||
| Gross Profit Before Fair Value Adjustment of Biological Assets | 4,753 | 4,017 | 14,971 | 11,923 | ||||||||
| Realized fair value amounts included in inventory sold | (375 | ) | (584 | ) | (1,407 | ) | (1,678 | ) | ||||
| Unrealized gain on changes in fair value of biological assets | 480 | 170 | 1,356 | 1,506 | ||||||||
| Gross Profit | 4,858 | 3,603 | 14,920 | 11,751 | ||||||||
| Gross Profit Margin | 53% | 44% | 53% | 44% | ||||||||
| Operating expenses | 5,960 | 8,592 | 17,975 | 23,165 | ||||||||
| Operating Loss | (1,102 | ) | (4,989 | ) | (3,055 | ) | (11,414 | ) | ||||
| Other items (Impairment, FV adjustment, FX, gains/losses, taxes, etc.) | (3,392 | ) | 348 | (7,304 | ) | (1,284 | ) | |||||
| Total Comprehensive Loss | (4,494 | ) | (4,641 | ) | (10,359 | ) | (12,698 | ) | ||||
| Earnings Per Share From Continuing Operations | ||||||||||||
| Basic | (0.03 | ) | (0.06 | ) | (0.06 | ) | (0.16 | ) | ||||
| Diluted | (0.03 | ) | (0.06 | ) | (0.06 | ) | (0.15 |
) | ||||
| （除每股數據和百分比外，以千加元計） | |
在結束的三個月裏 | 在結束的九個月裏 | | ||||||||
| 9 月 30 日-23 | 22 年 9 月 30 日 | 9 月 30 日-23 | 22 年 9 月 30 日 | |||||||||
| 來自持續經營業務的淨營業收入 | 9,101 | 8,170 | 28,360 | 26,412 | ||||||||
| 銷售商品的成本 | 4,348 | 4,153 | 13,389 | 14,489 | ||||||||
| 生物資產公允價值調整前的毛利潤 | 4,753 | 4,017 | 14,971 | 11,923 | ||||||||
| 已售庫存中包含的已實現公允價值金額 | (375 | ) | (584) | ) | (1,407 | ) | (1,678) | ) | ||||
| 生物資產公允價值變動產生的未實現收益 | 480 | 170 | 1,356 | 1,506 | ||||||||
| 毛利 | 4,858 | 3,603 | 14,920 | 11,751 | ||||||||
| 毛利率 | 53% | 44% | 53% | 44% | ||||||||
| 運營費用 | 5,960 | 8,592 | 17,975 | 23,165 | ||||||||
| 營業虧損 | (1,102) | ) | (4,989) | ) | (3,055) | ) | (11,414) | ) | ||||
| 其他項目（減值、FV 調整、外匯、收益/虧損、稅收等） | (3,392 | ) | 348 | (7,304 | ) | (1,284) | ) | |||||
| 綜合損失總額 | (4,494) | ) | (4,641) | ) | (10,359 | ) | (12,698 | ) | ||||
| 持續經營的每股收益 | ||||||||||||
| 基本 | (0.03 | ) | (0.06 | ) | (0.06 | ) | (0.16) | ) | ||||
| 稀釋 | (0.03 | ) | (0.06 | ) | (0.06 | ) | (0.15) |
) | ||||
| (In thousands of Canadian dollars) | For the three months ended | | For the nine months ended | |||||||||
| 30-Sep-23 | 30-Sep-22 | 30-Sep-23 | 30-Sep-22 | | ||||||||
| Net Operating Revenue From Continuing Operations | 9,101 | 8,170 | 28,360 | 26,412 | ||||||||
| Cost of Goods Sold | 4,348 | 4,153 | 13,389 | 14,489 | ||||||||
| Realized fair value amounts included in inventory sold | (375 | ) | (584 | ) | (1,407 | ) | (1,678 | ) | ||||
| Unrealized gain on fair value of biological assets | 480 | 170 | 1,356 | 1,506 | ||||||||
| Cost of Goods Sold | 4,243 | 4,567 | 13,440 | 14,661 | ||||||||
| Gross Profit | 4,858 | 3,603 | 14,920 | 11,751 | ||||||||
| Gross Profit Margin | 53% | 44% | 53% | 44% | ||||||||
| Gross Profit before FV adjustment | 4,753 | 4,017 | 14,971 | 11,923 | ||||||||
| Gross Profit Margin before FV adjustment | 52% | 49% | 53% | 45% | | |||||||
| （以千加元計） | 在結束的三個月裏 | | 在結束的九個月裏 | |||||||||
| 9 月 30 日-23 | 22 年 9 月 30 日 | 9 月 30 日-23 | 22 年 9 月 30 日 | | ||||||||
| 來自持續經營業務的淨營業收入 | 9,101 | 8,170 | 28,360 | 26,412 | ||||||||
| 商品銷售成本 | 4,348 | 4,153 | 13,389 | 14,489 | ||||||||
| 已售庫存中包含的已實現公允價值金額 | (375 | ) | (584) | ) | (1,407 | ) | (1,678) | ) | ||||
| 生物資產公允價值的未實現收益 | 480 | 170 | 1,356 | 1,506 | ||||||||
| 商品銷售成本 | 4,243 | 4,567 | 13,440 | 14,661 | ||||||||
| 毛利 | 4,858 | 3,603 | 14,920 | 11,751 | ||||||||
| 毛利率 | 53% | 44% | 53% | 44% | ||||||||
| FV 調整前的毛利潤 | 4,753 | 4,017 | 14,971 | 11,923 | ||||||||
| FV 調整前的毛利率 | 52% | 49% | 53% | 45% | | |||||||
| (In thousands of Canadian dollars) | For the three months ended | For the nine months ended | | |||||||||
| 30-Sep-23 | 30-Sep-22 | 30-Sep-23 | 30-Sep-22 | |||||||||
| Total Comprehensive Loss | (4,494 | ) | (4,641 | ) | (10,359 | ) | (12,698 | ) | ||||
| EBITDA (Non-IFRS) | (379 | ) | (3,432 | ) | (869 | ) | (6,887 | ) | ||||
| Adjusted EBITDA (Non-IFRS) | (306 | ) | (1,240 | ) | (328 | ) | (3,588 | ) | ||||
| （以千加元計） | 在結束的三個月裏 | 在結束的九個月裏 | | |||||||||
| 9 月 30 日-23 | 22 年 9 月 30 日 | 9 月 30 日-23 | 22 年 9 月 30 日 | |||||||||
| 綜合虧損總額 | (4,494) | ) | (4,641) | ) | (10,359 | ) | (12,698 | ) | ||||
| 息稅折舊攤銷前利潤（非國際財務報告準則） | (379) | ) | (3,432 | ) | (869) | ) | (6,887) | ) | ||||
| 調整後的息稅折舊攤銷前利潤（非國際財務報告準則） | (306) | ) | (1,240 | ) | (328 | ) | (3,588) | ) | ||||
See the Company's management's discussion and analysis for the three and nine months ended September 30, 2023 (the "Q3 2023 MD&A") for a detailed reconciliation of EBITDA and Adjusted EBITDA to Operating Income / (Loss). SLANG's financial statements and the Q3 2023 MD&A are available on SEDAR at , and on the Company's Investor Relations website at .
查看公司管理層對截至2023年9月30日的三個月和九個月的討論和分析（”2023 年第三季度 MD&A“），詳細覈對息稅折舊攤銷前利潤和調整後的息稅折舊攤銷前利潤與營業收入/（虧損）。SLANG的財務報表和2023年第三季度的MD&A可在SEDAR上查閱，也可在公司的投資者關係網站上查閱，網址爲。
Non-IFRS Measures
非國際財務報告準則指標
EBITDA, Adjusted EBITDA, adjusted gross profit and adjusted gross margin are non-IFRS financial measures that the Company uses to assess its operating performance. EBITDA is defined as net earnings (loss) before net finance costs, income tax expense (benefit) and depreciation and amortization expense. Management defines Adjusted EBITDA as EBITDA adjusted for other non-cash items such as the impact of unrealized fair values, share based compensation expense, impairments, one-time gains and losses, and one-time revenues and expenses. Management defines adjusted gross profit as gross profit before fair value adjustment of biological assets. Management defines adjusted gross margin as gross margin before fair value adjustment of biological assets. This data is furnished to provide additional information and are non-IFRS measures and do not have any standardized meaning prescribed by IFRS. The Company uses these non-IFRS measures to provide shareholders and others with supplemental measures of its operating performance. The Company also believes that securities analysts, investors and other interested parties, frequently use these non-IFRS measures in the evaluation of companies, many of which present similar metrics when reporting their results. As other companies may calculate these non-IFRS measures differently than the Company, these metrics may not be comparable to similarly titled measures reported by other companies. We caution readers that Adjusted EBITDA should not be substituted for determining net loss as an indicator of operating results, or as a substitute for cash flows from operating and investing activities. During 2022 the Company updated its definition of Adjusted EBITDA to include the impact of fair value amounts included in inventory sold and unrealized gain on changes in fair value of biological assets. Certain of the comparative 2022 figures have been updated to conform to this current period presentation.
息稅折舊攤銷前利潤、調整後的息稅折舊攤銷前利潤、調整後的毛利率是公司用來評估其經營業績的非國際財務報告準則財務指標。息稅折舊攤銷前利潤定義爲扣除淨財務成本、所得稅支出（收益）以及折舊和攤銷費用前的淨收益（虧損）。管理層將調整後的息稅折舊攤銷前利潤定義爲根據其他非現金項目進行調整的息稅折舊攤銷前利潤，例如未實現公允價值的影響、基於股份的薪酬支出、減值、一次性損益以及一次性收入和支出。管理層將調整後的毛利定義爲生物資產公允價值調整前的毛利。管理層將調整後的毛利率定義爲生物資產公允價值調整前的毛利率。提供這些數據是爲了提供更多信息，是非國際財務報告準則的衡量標準，不具有《國際財務報告準則》規定的任何標準化含義。公司使用這些非國際財務報告準則指標爲股東和其他人提供其經營業績的補充衡量標準。該公司還認爲，證券分析師、投資者和其他利益相關方在評估公司時經常使用這些非國際財務報告準則衡量標準，其中許多公司在報告業績時會提供相似的指標。由於其他公司計算這些非國際財務報告準則指標的方式可能與公司不同，因此這些指標可能無法與其他公司報告的標題相似的指標進行比較。我們提醒讀者，調整後的息稅折舊攤銷前利潤不應取代將淨虧損作爲經營業績的指標，也不能代替來自運營和投資活動的現金流。2022年，公司更新了調整後息稅折舊攤銷前利潤的定義，將出售庫存中包含的公允價值金額和未實現收益對生物資產公允價值變化的影響包括在內。2022年的某些比較數據已更新，以符合本期列報。
Conference Call Details
電話會議詳情
Management plans to host an investor conference call today, November 28, at 10:00 am ET to discuss the results.
管理層計劃於今天，即美國東部時間11月28日上午10點舉行投資者電話會議，討論業績。
Timing: Tuesday, November 28, 2023 at 10:00 am ET
Dial In: 1-(888) 440-5983 (US toll-free) or 1-(646) 960-0202 (international)
Conference ID: 6291438
Webcast: A live webcast can be accessed via the Company's website at or
時機: 美國東部時間 2023 年 11 月 28 日星期二上午 10:00
撥入: 1-(888) 440-5983（美國免費電話）或 1-(646) 960-0202（國際）
會議 ID: 6291438
網絡直播: 可以通過公司的網站訪問網絡直播，網址爲
About SLANG Worldwide
關於 SLANG 環球語
SLANG Worldwide Inc. is the industry leader in branded cannabis consumer packaged goods, with a diversified portfolio of five distinct brands and products distributed across the U.S. Operating in 13 legal cannabis markets nationwide, SLANG specializes in acquiring and developing market-proven regional brands, as well as launching innovative new brands to seize global market opportunities and match evolving consumer tastes. The Company has over a decade of experience operating in the nascent and highly regulated cannabis sector, and its partners enjoy the benefits of that experience, with access to the SLANG playbook for successful operations, sales and marketing. Its strong product pipeline from uniquely positioned and scalable brands like O.pen, Alchemy Naturals, Ceres, Firefly, and partnerships with brands like Greenhouse Seed Company have a proven track record of success with the brands consistently ranking among the top performers in the states where SLANG operates. Learn more at slangww.com.
SLANG Worldwide Inc. 是品牌大麻消費品包裝行業的領導者，擁有五個不同的品牌和產品的多元化產品組合，分佈在美國各地。SLANG 在全國13個合法的大麻市場開展業務，專門收購和開發經過市場驗證的區域品牌，並推出創新的新品牌以抓住全球市場機遇並滿足不斷變化的消費者品味。該公司在新興且受到嚴格監管的大麻行業擁有十多年的運營經驗，其合作伙伴可以從中受益，他們可以獲得SLANG的成功運營、銷售和營銷手冊。其強大的產品線來自O.pen、Alchemy Naturals、Ceres、Firefly等具有獨特定位和可擴展性的品牌，以及與Greenhouse Seed Company等品牌的合作伙伴關係，有着良好的成功記錄，這些品牌在SLANG運營所在州一直位居表現最佳的品牌之列。要了解更多信息，請訪問 slangww.com。
Forward-Looking Statements
前瞻性陳述
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur.
本新聞稿包含構成 “前瞻性陳述” 的陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致實際業績、業績或成就或行業發展與此類前瞻性陳述所表達或暗示的預期業績、業績或成就存在重大差異。前瞻性陳述不是歷史事實，通常但並非總是以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛在” 和類似表達方式來識別，或者說事件或條件 “將”、“將”、“可能” 或 “應該” 發生。
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management of SLANG at this time, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that could cause actual results to differ materially from those expressed or implied in such statements. Investors are cautioned not to put undue reliance on forward-looking statements. Applicable risks and uncertainties include, but are not limited to regulatory risks, risks related to the COVID-19 global pandemic, changes in laws, resolutions and guidelines, market risks, concentration risks, operating history, competition, the risks associated with international and foreign operations and the other risks identified under the headings "Risk Factors" in SLANG's annual information form dated April 27, 2022 and other disclosure documents available on SEDAR+ at . SLANG is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
前瞻性陳述必然基於許多估計和假設，儘管SLANG管理層目前認爲這些估計和假設是合理的，但本質上會受到重大的業務、經濟和競爭風險、不確定性和突發事件的影響，這些風險和不確定性和突發事件可能導致實際業績與此類陳述中表達或暗示的結果存在重大差異。提醒投資者不要過分依賴前瞻性陳述。適用的風險和不確定性包括但不限於監管風險、與 COVID-19 全球疫情相關的風險、法律、決議和指導方針的變化、市場風險、集中風險、運營歷史、競爭、與國際和國外業務相關的風險以及SEDAR+上提供的其他披露文件中在 “風險因素” 標題下確定的其他風險。除非適用法律明確要求，否則SLANG沒有義務更新或修改任何前瞻性信息，無論是由於新信息、未來事件還是其他原因，也明確表示不承擔任何意圖或義務。
Third Party Information
第三方信息
This press release includes market and industry data that has been obtained from third party sources, including industry publications. The Company believes that the industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this press release or ascertained the underlying economic assumptions relied upon by such sources.
本新聞稿包括從第三方來源（包括行業出版物）獲得的市場和行業數據。公司認爲行業數據是準確的，其估計和假設是合理的，但無法保證這些數據的準確性或完整性。第三方消息來源通常表示，其中包含的信息是從據信可靠的來源獲得的，但無法保證所含信息的準確性或完整性。儘管據信這些數據是可靠的，但該公司尚未獨立驗證本新聞稿中提及的來自第三方來源的任何數據，也沒有確定這些來源所依賴的基本經濟假設。
Reader Advisory
讀者諮詢
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所和加拿大投資行業監管組織均不對本新聞稿的充分性或準確性承擔責任。
Company Contact
Mikel Rutherford, CFO
833-752-6499
公司聯繫人
首席財務官米克爾·盧瑟福
833-752-6499
Media and Investor Inquiries
Investors@SLANGww.com
媒體和投資者查詢
Investors@SLANGww.com
KCSA Strategic Communications
Phil Carlson
SLANG@kcsa.com
KCSA 戰略傳播
菲爾·卡爾森
SLANG@kcsa.com
1 See "Non IFRS measures".
1 見 “非國際財務報告準則衡量標準”。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。